Protein C News and Research

RSS

Robust T cell and humoral immune response to SARS-CoV-2 in patients with immunodeficiency

A study of immune-deficient adults and children has shown that patients who fail to respond positively to infections and vaccinations have robust humoral immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) structural proteins.

18 May 2021

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

Researchers discovered the first N440K variant and the new E484Q and L452R Indian variants isolated in France in a recent study. They presented the genetic mutations in the isolated genomes and the phylogenetic tree, including these strains among different SARS-CoV-2 clades. This work is posted on the bioRxiv preprint server.

18 May 2021

Researchers identify specific influenza targets that could lead to universal flu vaccine for indigenous populations

Researchers have identified specific influenza targets that could be used to better protect Indigenous people from experiencing severe influenza disease through a universal, T cell-based vaccine.

18 May 2021

Higher levels of inflammatory proteins in the blood are associated with aggressive traits

Aggression is common in many neuropsychiatric diseases, such as dementia, autism spectrum disorder, and schizophrenia.

18 May 2021

Researchers report promising biotherapeutics for obesity and related medical complications

The research teams at the University of Hong Kong led by Professor Xuechen LI from the Research Division for Chemistry and Department of Chemistry, and Professor Yu WANG from the Department of Pharmacology and Pharmacy, reported a synthetic biotherapeutics with promising anti-tumor, insulin sensitising and hepatoprotective activities in the Journal of the American Chemical Society.

18 May 2021

New imaging technique helps reveal the best antibodies for COVID-19 detection

Vaccines are turning the tide of the pandemic, but the risk of infection is still present in some situations. If you want to visit a friend, get on a plane, or go see a movie, there is no highly accurate, instant test that can tell you right then and there whether or not you have a SARS-CoV-2 infection.

18 May 2021

Study provides new basis to compare the effectiveness of different tuberculosis treatments

A new study published in Nature Communications provides an important new basis for comparing the effectiveness of different tuberculosis treatments.

18 May 2021

SpaceX study profiles evolution of antibody response during COVID-19 infection

New research published on the preprint server bioRxiv* suggests S2-specific antibody responses are critical in recovering from mild to severe COVID-19 infection. Compared to patients who died within 28 days of their COVID-19 diagnosis, patients who produced a wide range of S2-specific responses were more likely to survive.

18 May 2021

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

A team of scientists from the USA and Belgium has recently revealed that the ErbB family of receptor tyrosine kinases play a vital role in regulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lifecycle in host cells and that inhibition of these receptors can protect against SARS-CoV-2-induced acute and chronic lung injuries and inflammation.

18 May 2021

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Researchers in the United States have demonstrated the long-term durability of the antibody responses elicited by Moderna’s mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 May 2021

Researchers investigate immune molecule that helps protect transplanted kidneys

Looking to improve organ transplant success, researchers are working to learn more about how an immune molecule, which also protects a fetus, helps protect some transplanted kidneys, and to develop a synthetic version of that molecule that could help more patients.

18 May 2021

A promising drug delivery system for therapeutics that shut down harmful genes

Viruses attack the body by sending their genetic code -- DNA and RNA -- into cells and multiplying. A promising class of therapeutics that uses synthetic nucleic acids to target and shut down specific, harmful genes and prevent viruses from spreading is gaining steam.

18 May 2021

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Researchers in the United States have developed stabilized immunogens presenting the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may improve the scalability of RBD-based coronavirus vaccines.

18 May 2021

Abnormal blood levels of proteins linked to dementia, Alzheimer's disease

The development of dementia, often from Alzheimer's disease, late in life is associated with abnormal blood levels of dozens of proteins up to five years earlier, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health

18 May 2021

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

Scientists at the University of Zurich have modified a common respiratory virus, called adenovirus, to act like a Trojan horse to deliver genes for cancer therapeutics directly into tumor cells. Unlike chemotherapy or radiotherapy, this approach does no harm to normal healthy cells.

18 May 2021

ACROBiosystems makes donations to BEI Resources, accelerating the process of attacking SARS-CoV-2 variants globally

Multiple SARS-CoV-2 variants are emerging and circulating globally; the battle against COVID-19 pandemic is still challenging. Recently, ACROBiosystems donated SARS-CoV-2 mutant proteins to BEI Resources, a NIAID funded bioresource program, joining in the collective effort in attacking SARS-CoV-2 variants globally.

From ACROBiosystems 17 May 2021

UNSW researchers find novel way to attack the 'fortress' surrounding pancreatic tumors

Tackling the scar tissue that shields pancreatic tumors from effective drug access is a promising advance in a notoriously hard-to-treat cancer.

17 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

Investigational drug reduced triglycerides in patients with severe hypertriglyceridemia, acute pancreatitis

The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by Mount Sinai.

17 May 2021

Nanopore analysis identifies pseudouridine modifications in SARS-CoV-2

In a paper recently uploaded to the preprint server bioRxiv* by Fleming, Mathewson & Burrows (May 10th, 2021), nanopore devices are developed that allow identification of the passage of pseudouridine through a protein sensor. This further allowed the group to identify five conserved pseudouridine sites on the 3’ end of SARS-CoV-2 sub-genomic RNAs, which could potentially be beneficial to the virus in immune evasion.

17 May 2021

Protein C News and Research

Robust T cell and humoral immune response to SARS-CoV-2 in patients with immunodeficiency

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

Researchers identify specific influenza targets that could lead to universal flu vaccine for indigenous populations

Higher levels of inflammatory proteins in the blood are associated with aggressive traits

Researchers report promising biotherapeutics for obesity and related medical complications

New imaging technique helps reveal the best antibodies for COVID-19 detection

Study provides new basis to compare the effectiveness of different tuberculosis treatments

SpaceX study profiles evolution of antibody response during COVID-19 infection

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Researchers investigate immune molecule that helps protect transplanted kidneys

A promising drug delivery system for therapeutics that shut down harmful genes

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Abnormal blood levels of proteins linked to dementia, Alzheimer's disease

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

ACROBiosystems makes donations to BEI Resources, accelerating the process of attacking SARS-CoV-2 variants globally

UNSW researchers find novel way to attack the 'fortress' surrounding pancreatic tumors

Nanotechnology and COVID-19 diagnosis and treatment

Investigational drug reduced triglycerides in patients with severe hypertriglyceridemia, acute pancreatitis

Nanopore analysis identifies pseudouridine modifications in SARS-CoV-2

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News